{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:43:21Z","timestamp":1795023801444,"version":"4.10.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ygyno.2021.03.019","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T07:09:43Z","timestamp":1616569783000},"page":"762-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mutational spectrum in clinically aggressive low-grade serous carcinoma\/serous borderline tumors of the ovary\u2014Clinical significance of BRCA2 gene variants in genomically stable tumors"],"prefix":"10.1016","volume":"161","author":[{"given":"Xiaoming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Devins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carolina","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yoon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.03.019_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0015","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2015.10.022","article-title":"Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide","volume":"141","author":"Singh","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2018.11.033","article-title":"The fallopian tube, \u201cprecursor escape\u201d and narrowing the knowledge gap to the origins of high-grade serous carcinoma","volume":"152","author":"Soong","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low- and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0035","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/modpathol.2011.106","article-title":"Tubal origin of \u2018ovarian\u2019 low-grade serous carcinoma","volume":"24","author":"Li","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0040","series-title":"Female Genital Tumours","volume":"vol. 4","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.neo.2019.03.014","article-title":"Loss of 1p36.33 frequent in low-grade serous ovarian cancer","volume":"21","author":"Van","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0050","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0055","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2017.08.021","article-title":"Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma","volume":"68","author":"Xing","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0065","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/PAS.0000000000001325","article-title":"Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma","volume":"43","author":"Chui","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/diagnostics10010013","article-title":"High frequency of PIK3CA mutations in low-grade serous ovarian carcinomas of Japanese patients","volume":"27","author":"Ishibashi","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0080","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2020.08.030","article-title":"mRNA expression in low grade serous ovarian cancer: results of a nanoString assay in a diverse population","volume":"159","author":"Jordan","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0085","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.gore.2015.03.007","article-title":"Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a \"low-grade serous tubal intra-epithelial carcinoma\" (STIC) on risk reducing surgery","volume":"12","author":"Chay","year":"2015","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0100","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0110","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/s41388-019-0883-6","article-title":"The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling","volume":"38","author":"Cui","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng1196-253","article-title":"A polymorphic stop codon in BRCA2","volume":"14","author":"Mazoyer","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/hmg\/8.3.413","article-title":"Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations","volume":"8","author":"Wagner","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0125","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jmedgenet-2015-103206","article-title":"The BRCA2 polymorphic stop codon: stuff or nonsense?","volume":"52","author":"Higgs","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0130","doi-asserted-by":"crossref","first-page":"14800","DOI":"10.1038\/srep14800","article-title":"Reevaluation of the BRCA2 truncating allele c.9976A>T (p.Lys3326Ter) in a familial breast cancer context","volume":"5","author":"Thompson","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jnci\/djy002","article-title":"Association of BRCA2 K3326* with small cell lung cancer and squamous cell cancer of the skin","volume":"110","author":"Rafnar","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/0008-5472.417.65.2","article-title":"Functional evaluation and cancer risk assessment of BRCA2 unclassified variants","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0145","doi-asserted-by":"crossref","first-page":"12813","DOI":"10.1038\/ncomms12813","article-title":"A second DNA binding site in human BRCA2 promotes homologous recombination","volume":"7","author":"von Nicolai","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0150","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0155","doi-asserted-by":"crossref","first-page":"21179","DOI":"10.1074\/jbc.M802333200","article-title":"Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences","volume":"283","author":"Fox","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12885-018-4153-8","article-title":"A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention","volume":"18","author":"Hanley","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0175","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2021.03.019_bb0180","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.03.019_bb0185","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:48:28Z","timestamp":1715820508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821002572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0090825821002572"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutational spectrum in clinically aggressive low-grade serous carcinoma\/serous borderline tumors of the ovary\u2014Clinical significance of BRCA2 gene variants in genomically stable tumors","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}